US Corporate Distress Financial Stress SEC Filings — August 21, 2026

21-08-2026

VivoSim Labs, Inc. received a Nasdaq deficiency notice on August 17, 2026, for failing to maintain a minimum bid price of $1 per share over 30 consecutive business days. The company has 180 days, until February 16, 2027, to regain compliance, and is considering a reverse stock split (ratio 1-for-5 to 1-for-20) subject to stockholder approval. However, there is no assurance of regaining compliance, and failure could lead to delisting.

• · The company's common stock continues to trade on the Nasdaq Capital Market under symbol VIVS with no immediate effect on listing.
• · If compliance is not achieved by February 16, 2027, the company may be eligible for an additional 180-day compliance period if it meets other listing standards.
• · A reverse stock split proposal has been included in the preliminary proxy statement for the 2026 Annual Meeting of Stockholders, filed on August 10, 2026.

21-08-2026

Global Interactive Technologies, Inc. (GITS) received a Nasdaq notification on August 20, 2026, for failing to timely file its Form 10-Q for the quarter ended June 30, 2026, violating Nasdaq Listing Rule 5250(c)(1). The company has 60 days to submit a compliance plan and expects to file the Form 10-Q promptly. Its common stock continues to trade on Nasdaq during the grace period.

• · The company is an emerging growth company.
• · If Nasdaq accepts the compliance plan, the exception can extend until February 16, 2027.
• · The press release was issued on August 21, 2026.

21-08-2026

Citius Pharmaceuticals, Inc. (CTXR) received an extension from Nasdaq until February 8, 2027, to regain compliance with the $1.00 minimum bid price rule. The company must close at or above $1.00 for at least ten consecutive business days before that deadline to avoid delisting. While the stock continues to trade on the Nasdaq Capital Market, there is no assurance that compliance will be achieved.

• · The extension deadline is February 8, 2027.
• · Compliance requires the bid price to close at $1.00 or more for a minimum of ten consecutive business days.
• · If compliance is not regained by the deadline, Nasdaq will issue a delisting notice, and the company may appeal to a hearings panel.
• · The company is evaluating options to regain compliance but cannot guarantee success.

21-08-2026

Silexion Therapeutics Corp received a delisting notice from Nasdaq on August 18, 2026, for failing to meet the minimum shareholders' equity requirement of $2,500,000 under Listing Rule 5550(b)(1). As of June 30, 2026, the company reported shareholders' equity of only $44,000, and subsequent net losses have further eroded equity. The company intends to appeal the determination by August 25, 2026, but there is no assurance of success; failure could result in suspension of trading and removal of its securities from Nasdaq.

• · The company is under a Mandatory Hearings Panel Monitor per Nasdaq Listing Rule 5815(d)(4)(B) following a Panel decision dated September 23, 2025, which prevents the Nasdaq Listing Qualifications Department from granting additional time to regain compliance during the one-year monitoring period.
• · The company does not currently meet any of the alternative continued listing standards of The Nasdaq Capital Market.
• · The company's ordinary shares (SLXN) and warrants (SLXNW) are both listed on Nasdaq and would be subject to suspension and delisting if the appeal is unsuccessful.

21-08-2026

BioCardia, Inc. received a Nasdaq notice on August 19, 2026, for failing to maintain the minimum $1.00 bid price per share for 30 consecutive business days. The company has 180 calendar days (until February 16, 2027) to regain compliance by having a closing bid price of $1.00 or more for at least ten consecutive business days. While the notice has no immediate effect on trading, failure to cure could lead to eventual delisting, though additional time or a reverse stock split may be pursued.

• · Minimum bid price requirement: $1.00 per share for continued listing on Nasdaq Capital Market.
• · Compliance can be achieved if closing bid price is $1.00 or more for ten consecutive business days by February 16, 2027.
• · If not cured by February 16, 2027, the company may qualify for an additional 180-day compliance period if it meets other listing standards and intends to effect a reverse stock split.
• · If delisting occurs, the company can appeal to a Nasdaq hearings panel.

21-08-2026

loanDepot, Inc. received a NYSE notice on August 21, 2026, for non-compliance with the minimum share price rule (average closing price below $1.00 over 30 consecutive trading days). The company has a six-month cure period to regain compliance, during which the stock remains listed. The notice does not affect business operations or SEC reporting obligations, but failure to cure could lead to suspension and delisting.

• · The company must notify the NYSE of its intent to cure within 10 business days of the notice.
• · Compliance can be regained if on the last trading day of any calendar month during the cure period, the stock closes at or above $1.00 and has a 30-day average closing price of at least $1.00.
• · If the cure requires shareholder approval, the company must obtain it by the next annual meeting and implement the action promptly.

21-08-2026

Rain Enhancement Technologies Holdco, Inc. (RAIN/RAINW) received a delisting notice from Nasdaq on August 18, 2026, after failing to regain compliance with the $35 million market value of listed securities (MVLS) requirement within the 180-day cure period ending August 17, 2026. The company has timely requested a hearing before the Nasdaq Hearings Panel, which will stay any suspension or delisting pending the hearing, but there is no assurance the panel will grant continued listing relief.

• · Initial MVLS notice received on February 18, 2026, for 30 consecutive business days ended February 17, 2026.
• · Cure period expired on August 17, 2026; company failed to regain compliance.
• · Suspension and delisting scheduled for August 27, 2026, if no hearing request.
• · Hearing request submitted on August 21, 2026, stays delisting pending hearing outcome.
• · Company is considering all options to regain compliance.

21-08-2026

TruGolf Holdings, Inc. (TRUG) received a Nasdaq delisting notice on August 19, 2026, for failing to meet the minimum $2.5 million stockholders' equity requirement, reporting only $2,060,281. The company has until October 5, 2026, to submit a compliance plan, with a possible extension to February 15, 2027. Meanwhile, the company is proceeding with the acquisition of Polymath Research Inc. via amalgamation, and a significant conversion of Series A preferred stock into common shares has occurred, with 2,688,750 shares issued and approximately $4.4 million in stated value still outstanding, which could further dilute existing shareholders.

• · The company has 45 calendar days (until October 5, 2026) to submit a compliance plan to Nasdaq.
• · If the plan is accepted, Nasdaq can grant an extension of up to 180 calendar days (until February 15, 2027) to evidence compliance.
• · The Series A preferred stock conversion price was reset to $1.00 per share.
• · The company's Class A common stock will continue trading under symbol 'TRUG' during the process.
• · There is no assurance that the company will regain compliance or maintain other listing requirements.

21-08-2026

Pasithea Therapeutics Corp. (KTTAW) disclosed on August 21, 2026 that it received a notice from Nasdaq on August 20, 2026 granting a 180-day extension to February 16, 2027 to regain compliance with the minimum $1.00 bid price requirement for continued listing on the Nasdaq Capital Market. The company previously failed to meet the Minimum Bid Price Requirement and its initial 180-day grace period ended August 19, 2026. While the extension provides temporary relief, there is no assurance the company will regain compliance, and failure to do so would result in delisting proceedings.

• · Company first received a non-compliance notice on February 20, 2026, triggering a 180-day grace period ending August 19, 2026.
• · The extension pushes the compliance deadline to February 16, 2027.
• · Company may consider a reverse stock split to regain compliance.
• · If compliance is not regained by February 16, 2027, Nasdaq will issue a delisting notice; company may appeal to a Nasdaq hearings panel.
• · Common stock trades under symbol KTTAW on the Nasdaq Capital Market.

21-08-2026

Dragonfly Energy Holdings Corp. received a Nasdaq deficiency notice on August 20, 2026, for failing to meet the minimum stockholders' equity requirement of $2.5 million, reporting a negative equity of $(184,000) as of June 30, 2026. The company also did not meet alternative compliance standards based on market value of listed securities ($35 million) or net income from continuing operations ($500,000). The company has 45 days (until October 5, 2026) to submit a compliance plan, and if accepted, Nasdaq may grant an extension until February 16, 2027; however, there is no assurance of acceptance or future compliance.

• · The company's common stock (DFLI) and warrants (DFLIW) continue to trade on Nasdaq pending the compliance process.
• · If Nasdaq rejects the plan, the company has the right to appeal to a Nasdaq hearings panel.
• · The company is an emerging growth company and has not elected the extended transition period for new accounting standards.

21-08-2026

authID Inc. received a deficiency notice from Nasdaq on August 18, 2026, for failing to meet the minimum stockholders' equity requirement of $2,500,000 under Listing Rule 5550(b)(1). The company reported stockholders' equity of only $2,042,515 as of June 30, 2026, and also does not satisfy the alternative market value or net income tests. While the stock continues to trade under the symbol AUID, the company has 45 days (until October 2, 2026) to submit a compliance plan, and there is no assurance that Nasdaq will accept the plan or that compliance can be regained.

• · The deficiency notice has no immediate effect on the listing or trading of AUID common stock.
• · If Nasdaq rejects the plan or compliance is not regained within the extension, the company may appeal to an independent Nasdaq Hearings Panel, which could grant an additional 180 days.
• · The filing includes a cautionary note about forward-looking statements, highlighting risks such as the ability to raise additional capital and substantial doubt about going concern.

21-08-2026

Estrella Immunopharma, Inc. received a Nasdaq deficiency notice on August 17, 2026, for failing to maintain a minimum bid price of $1.00 per share for its common stock (ESLA) for 30 consecutive business days. The company has until February 16, 2027, to regain compliance, and its stock continues trading in the interim. Failure to cure could lead to delisting.

• · The company may be eligible for an additional 180-day compliance period if it meets other listing standards.
• · If a reverse stock split is used to regain compliance, it must be completed at least 10 business days before the compliance deadline.
• · The company's stock symbols are ESLA (common stock) and ESLAW (warrants).
• · Warrants have an exercise price of $11.50 per share.

21-08-2026

Adial Pharmaceuticals received a Nasdaq notice on August 18, 2026, for failing to meet the minimum stockholders' equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market. The company has 45 days (until October 2, 2026) to submit a compliance plan and intends to seek stockholder approval to convert its Series A Preferred Stock to regain compliance, but there is no assurance of success. If the plan is accepted, Nasdaq may grant an extension of up to 180 days; if not, the company faces potential delisting.

• · The company also does not meet the alternative quantitative standards: market value of listed securities of $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the last three fiscal years.
• · The Notice has no immediate effect on trading; the stock remains listed pending compliance efforts.
• · If the compliance plan is not accepted or fails, the company can request a hearing before Nasdaq's Hearing Panel, which would stay any suspension or delisting action pending the hearing process.

21-08-2026

SolarMax Technology, Inc. (SMXT) received a Nasdaq notice on August 20, 2026, for failing to file its Form 10-Q for the quarter ended June 30, 2026, violating Listing Rule 5250(c)(1). The company has 60 days (until October 19, 2026) to submit a compliance plan, with a possible extension to February 16, 2027. This is the third Nasdaq deficiency notice in 2026, adding to prior failures to meet the minimum bid price of $1.00 (deadline August 31, 2026) and the market value of listed securities requirement of at least $35 million (deadline December 21, 2026). The company effected a 1-for-12 reverse stock split on August 13, 2026, to address the bid price issue, but the cumulative listing challenges signal significant financial and operational distress.

• · The company has received three separate Nasdaq deficiency notices in 2026: for failure to file Form 10-Q (June 30, 2026 quarter), for minimum bid price below $1.00 (deadline August 31, 2026), and for market value of listed securities below $35 million (deadline December 21, 2026).
• · The reverse stock split (1-for-12) was effected on August 13, 2026, to address the bid price deficiency.
• · If Nasdaq accepts the compliance plan, the company could have until February 16, 2027 to regain full compliance with the filing requirement.

21-08-2026

Flash Sports & Media Holdings, Inc. (formerly urban-gro, Inc.) received a Staff Determination from Nasdaq on August 19, 2026, stating that its securities are subject to immediate suspension due to the timing and sequencing of its initial listing application process following a reverse merger and conversion of Series B Preferred Stock into 53,539,119 common shares. The company intends to request a hearing before a Nasdaq Hearings Panel by August 26, 2026, to seek reinstatement, but trading is set to be suspended at the opening of business on that same day. The delisting risk could adversely affect the liquidity and market price of the company's common stock.

• · The reverse merger was completed on February 17, 2025.
• · Nasdaq Staff determined on February 24, 2026, that the transaction constituted a 'Change of Control' under Nasdaq Listing Rule 5110(a).
• · Stockholders approved removal of the 19.9% conversion cap on June 12, 2026.
• · Conversion of Series B Preferred Stock occurred on June 23, 2026.
• · The Staff Determination concerns only the timing/sequencing of the listing application, not a substantive deficiency with the company or its business.
• · Trading suspension is scheduled for the opening of business on August 26, 2026.
• · The hearing request deadline is 4:00 p.m. Eastern Time on August 26, 2026.

21-08-2026

Synergy CHC Corp. received a Nasdaq notice on August 20, 2026, for non-compliance with Listing Rule 5250(c)(1) due to the delayed filing of its Q2 2026 Form 10-Q. The company has 60 days to submit a compliance plan and up to 180 days to regain compliance, but management cannot assure when or if the filing will be made. This development introduces significant uncertainty regarding the company's continued listing on Nasdaq.

• · The company has 60 calendar days (until October 19, 2026) to submit a compliance plan to Nasdaq.
• · Nasdaq may grant up to 180 calendar days from the Q2 Form 10-Q due date (until February 10, 2027) to regain compliance.
• · The notice has no immediate effect on the listing or trading of SNYR common stock.
• · The company's flagship brands include FOCUSfactor (brain health supplement) and Flat Tummy (women's wellness).